Compare FGBI & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | INO |
|---|---|---|
| Founded | 1934 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 118.9M |
| IPO Year | 2014 | 1999 |
| Metric | FGBI | INO |
|---|---|---|
| Price | $8.84 | $1.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 14.0K | ★ 3.2M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | $567.70 | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | $28.00 | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $4.31 | $0.56 |
| 52 Week High | $11.02 | $2.72 |
| Indicator | FGBI | INO |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 53.35 |
| Support Level | $8.24 | $1.22 |
| Resistance Level | $8.86 | $1.24 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 93.20 | 43.24 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana through several banking facilities. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and, to a lesser extent, consumer and multifamily loans. The company is engaged in a single line of business as a financial institution, which provides a full range of banking, financial, and trust services to state, county, and local government entities, individuals, and small and commercial businesses.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.